Compare AstraZeneca plc (AZN) vs Genuine Parts Company (GPC) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

GPC trades at $123.52, down 1.67% over the past day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results expected on July 21, 2026. Revenue growth remains modest at $24.3B in 2025, though net income margins have compressed significantly to 0.24%. Analyst sentiment is mixed with a consensus price target of $133.00, representing a 7.7% upside from current levels.

GPC offers potential for moderate upside based on analyst targets and dividend stability, but faces headwinds from declining profitability margins and recent earnings misses. The stock's high P/E ratio of 280.73 suggests premium valuation despite weak earnings growth, while strong cash flow generation and Dividend King status provide some downside protection. Key risks include margin pressure and competitive threats in the automotive parts distribution sector.